The Affordable Frontier: Biosimilar Immunotherapy Reshapes Cancer Care in India

May 7, 2026

NEW DELHI — In a move that marks a paradigm shift for oncology in the developing world, a new wave of affordable biosimilar immunotherapies is fundamentally altering the treatment landscape for cancer patients across India. As of early 2026, the introduction of cost-effective alternatives to “blockbuster” drugs—specifically the world’s first biosimilar of Nivolumab—has slashed treatment expenses by as much as 70%. For a nation grappling with a surging cancer crisis and high out-of-pocket healthcare costs, this pharmaceutical milestone is transforming immunotherapy from a luxury for the elite into a viable lifeline for the masses.

A Breakthrough in Access

For years, immune checkpoint inhibitors represented the “gold standard” of modern oncology, yet they remained financially out of reach for the vast majority of Indian patients. This changed in January 2026, when Zydus Lifesciences launched Tishtha™, the world’s first biosimilar of Nivolumab.

Nivolumab is a programmed death-1 (PD-1) inhibitor that “unmasks” cancer cells, allowing the body’s own immune system to identify and destroy them. While the originator drug (Opdivo®) revolutionized the treatment of lung cancer, Hodgkin lymphoma, and renal cell carcinoma, its price tag meant that nearly 80% of eligible Indian patients were forced to opt for less effective, traditional chemotherapies.

“We are seeing a dramatic shift in the clinic,” says Dr. Nitesh Rohatgi, Principal Director of Medical Oncology at Fortis Memorial Research Institute, Gurugram. “About 60% to 70% of new patients being started on Nivolumab are now receiving the biosimilar. The relief on patients’ faces when they realize they can afford a therapy previously deemed impossible is profound.”

By the Numbers: The Cost Revolution

*Projected price via public-private partnerships and patient assistance programs.

Understanding Biosimilars: Accuracy vs. Identity

To understand this revolution, one must distinguish biosimilars from generic drugs. While generics are exact chemical copies of simple pills like aspirin, biosimilars are grown in living cells. They are “highly similar” to the original biologic drug, with no clinically meaningful differences in terms of safety, purity, or potency.

The Central Drugs Standard Control Organisation (CDSCO), India’s regulatory body, approved Tishtha™ following a rigorous pathway that included structural characterization and clinical trials in non-small cell lung cancer (NSCLC).

“The regulatory bar for biosimilars is exceptionally high,” explains Dr. Ankur Bahl, a leading medical oncologist. “These are not shortcuts; they are sophisticated biological engineering. The Delhi High Court’s ruling to allow this entry has cleared the path for a level of competition that benefits the patient directly.”

Facing the “Cancer Tsunami”

The timing of this innovation is critical. According to data from the Indian Council of Medical Research (ICMR), India recorded 1.56 million new cancer cases in 2024. Projections suggest this will surge to 2.46 million by 2045, driven by an aging population, tobacco use, and environmental factors.

Historically, 60% to 70% of cancer cases in India are diagnosed at advanced stages (III or IV). At these stages, traditional chemotherapy often yields limited survival benefits. Immunotherapy offers the hope of long-term remission, but only if it is accessible early in the treatment cycle.

“India’s adoption of affordable biosimilars is a model for the Global South,” notes Dr. Bassim Al Bahraini, Senior Consultant Medical Oncology at Royal Hospital Oman. “By moving from a 10% access rate to 80% among eligible patients, India is generating real-world evidence that will eventually inform global oncology guidelines.”

The Awareness Gap: A New Challenge

Despite the clinical success, a significant hurdle remains: the patient awareness chasm.

While oncologists are eager to prescribe these treatments, many patients and caregivers remain wary. Years of “chemotherapy” being synonymous with cancer treatment has created a psychological default. Many are unaware that immunotherapy often carries a different—and sometimes more manageable—side-effect profile than traditional “chemo.”

“Patients are invariably happy when we can offer these treatments at a fraction of the cost, but the education must start earlier,” says Dr. Rohatgi. “There is still a misconception that ‘cheaper’ means ‘inferior’ in medicine. We need public health campaigns to demystify biosimilars, much like the campaigns that built trust in generic medications twenty years ago.”

Key Differences: Immunotherapy vs. Chemotherapy

• Mechanism: Chemotherapy kills rapidly dividing cells (both healthy and cancerous); Immunotherapy trains the immune system to find the cancer.

• Side Effects: Chemotherapy often causes hair loss and nausea; Immunotherapy can cause “immune-related” inflammation (e.g., skin rashes or colitis).

• Durability: Immunotherapy can provide “durable responses,” where the immune system continues to fight the cancer even after treatment stops.

Limitations and the Road Ahead

While the “Biosimilar Revolution” is promising, experts urge a balanced perspective. Biosimilars are not identical twins to their originators. Minor structural variations, such as the pattern of sugars attached to the protein, could theoretically lead to immunogenicity—where the body’s immune system reacts against the drug itself.

Furthermore, while Zydus’ Nivolumab is approved for lung cancer, it is currently undergoing Phase IV (post-marketing) surveillance for other indications like gastric and bladder cancers.

“We must maintain strict pharmacovigilance,” cautions Dr. Bahl. “Any switch from an originator to a biosimilar should be done under the strict supervision of an oncologist to monitor for adverse events. We also need long-term data to ensure that the five-year survival rates match those seen in global trials for the originator.”

A Global Leader in Evidence

As the cost of treatment drops, India is positioned to become a global hub for “Real-World Evidence” (RWE). With a high volume of patients now receiving these therapies, Indian medical institutions will soon produce data on how these drugs perform across diverse genetic populations—data that Western trials often lack.

The shift toward biosimilars aligns with NITI Aayog’s incentives for domestic Research & Development, aiming to reduce India’s dependence on expensive imported biologics. For the average family, this means a diagnosis that once spelled certain financial ruin may now be a manageable chronic condition.

The revolution has begun, but as the medical community agrees, the next step is ensuring that every patient, from the metropolitan hubs to the rural heartlands, knows that “affordable” no longer means “out of reach.”

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Economic Times Health. “India Emerging as Major Market for Biosimilar Immunotherapy, But Patient Awareness Still Lags: Oncologists.” Published May 6, 2026.